WP1096
/ Moleculin
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 24, 2021
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020
(PRNewswire)
- “WP1122, WP1096 and WP1097 Portfolio…Working to initiate a Phase 1a/1b clinical trial in COVID-19 or a physician-sponsored clinical trial for a cancer indication, or both in 2021. Anticipated 2021 Milestones…Potential for 8 clinical trials in 2021, including 3 to be conducted by Moleculin and 5 primarily externally funded and conducted trials; External funding will be relied upon to the extent it is available.”
Clinical • New P1 trial • Brain Cancer • Glioblastoma • Oncology
1 to 1
Of
1
Go to page
1